- Conditions
- CROHN'S DISEASE
- Interventions
- Immune Ablation and Hematopoietic Stem Cell Support
- Biological
- Lead sponsor
- Richard Burt, MD
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lymphoma
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, paclitaxel, thiotepa, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Buffalo, New York • Cleveland, Ohio
- Conditions
- Lymphoma, B-cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Grade 3b, Follicular Lymphoma, Grade 3b
- Interventions
- denintuzumab mafodotin, rituximab, ifosfamide, carboplatin, etoposide
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 29
- States / cities
- Little Rock, Arkansas • Duarte, California • San Diego, California + 24 more
- Conditions
- High Risk Neuroblastoma
- Interventions
- Aldesleukin, Diagnostic Laboratory Biomarker Analysis, Dinutuximab, Isotretinoin, Sargramostim
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 32
- States / cities
- Loma Linda, California • Los Angeles, California • Orange, California + 25 more
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- Music Therapy, No music therapy
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Childhood Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Interventions
- busulfan, etoposide, aldesleukin, peripheral blood stem cell transplantation
- Drug · Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Multiple Myeloma, Plasma Cell Myeloma
- Interventions
- bortezomib, cisplatin, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, etoposide, lenalidomide, melphalan, thalidomide, gene expression analysis, microarray analysis, laboratory biomarker analysis, autologous-autologous tandem hematopoietic stem cell transplantation
- Drug · Genetic · Other + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 21
- States / cities
- Alexandria, Louisiana • Baton Rouge, Louisiana • Detroit, Michigan + 12 more
- Conditions
- Neuroblastoma
- Interventions
- filgrastim, monoclonal antibody 3F8, sargramostim, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, isotretinoin, thiotepa, topotecan hydrochloride, vincristine sulfate, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, drug resistance inhibition treatment, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Crohn's Disease
- Interventions
- autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, ATG, Melphalan, Thiotepa, Rituximab, Cyclophosphamide, G-CSF, Mesna
- Biological · Drug
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 10 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Lymphoma, Multiple Myeloma
- Interventions
- CMV-MVA Triplex Vaccine
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, nivolumab
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 13
- States / cities
- Duarte, California • Stanford, California • Boston, Massachusetts + 10 more
- Conditions
- DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Peripheral Blood Stem Cell Transplantation, Placebo Administration
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2027
- U.S. locations
- 140
- States / cities
- Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- filgrastim, cisplatin, cyclophosphamide, vincristine, autologous hematopoietic stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2023
- U.S. locations
- 4
- States / cities
- Durham, North Carolina • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, sargramostim, busulfan, carboplatin, cyclophosphamide, melphalan, paclitaxel, tamoxifen citrate, thiotepa, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- LMP2A-loaded conventional DC vaccine, DUK-CPG-001
- Biological
- Lead sponsor
- David Rizzieri, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 365 Days to 30 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
- Interventions
- filgrastim, carboplatin, ifosfamide, paclitaxel, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- dexamethasone, carfilzomib, lenalidomide, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • St Louis, Missouri + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Daratumumab/rHuPH20 Co-formulation
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Lansing, Michigan
- Conditions
- Multiple Sclerosis
- Interventions
- Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Thiotepa, Carmustine, Autologous Stem Cell Transplant, Anthracycline-based induction chemotherapy
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Multiple Myeloma
- Interventions
- Tremelimumab, Durvalumab, Prevnar-13, Melphalan
- Drug · Biological
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- New York, New York